



APC



1st African Patients Congress



20 - 21 July 2021 ● apc2021.pincrowdevents.com ● #APC2021

**African patient engagement in clinical research
and development of medicines, vaccines, and
health devices**

Adeline Edgal

CSO,SSA
Novartis Global Health

Commitment to Patients and Caregivers

“Working together, we can improve outcomes for patients and become a trusted partner in changing the practice of medicine”




Respecting and understanding the patient community perspective



Expanding access to our medicines



Conducting responsible clinical trials



Recognizing the importance of transparency and reporting

Sub Saharan Africa aspiration

Where we are now

- Clinical trials have been introduced to several countries within SSA
- Our trials are conducted with internal capabilities within the region
- We have several clinical trials being conducted in **the CD (Malaria) and NCD space (SCD)**




Where we want to be

- Build clinical trial capabilities in SSA and have a **larger proportion of black Africans involved in clinical trials.**
- Build on CD/ NCD trials in Kenya, Nigeria, Ghana, and Mauritius with a focus on cardiovascular, **with expansion to ophthalmology and oncology** therapeutic areas
- Giving the patient a voice to better understand their needs as regards clinical trials

How we want to get there

- Implement an in-house/insourcing management model for Trial Monitoring and Regulatory Affairs Clinical trials
- **Look for opportunities within our pipeline where we have a large burden of disease.**
- Allocate resources for ongoing capacity building initiatives.
- **Engage patient and patient groups/caregivers early on in building the protocols.**
- Introduction of **TFQ (trial feedback questionnaire)** to gather patients experience at trial sites.
- We also had discussions on the use of **patient awareness/friendly materials on importance of and benefits of clinical trials**




- Population 1,293,910,059 (Sept 9th, 2018 UN est.)
- 16.64% of the world population ; growth 2.52% p.a
- Median age 19.4 yrs vs. worldwide 30.4 yrs
- NCD 33.5% of all deaths in Africa up 29.4% 2010-15. They will be leading cause of death by 2030

<http://www.worldometers.info/world-population/#region> (retrieved on 15 July 2021)

World Bank Africa's Pulse Report, April 2018

Cancer rank as leading cause of death among 30-69

2016




SOURCES AND METHODS

World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. 2018.


The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the American Cancer Society concerning the legal status of any country, territory, city, or area of its authorities, or concerning the delimitation of its frontiers or boundaries.

Diseases of interest


Deaths from **cardiovascular** disease in 2015. n = 2.3 mill









Global deaths from **cancer** in 2012. n = 8.2 mill



WHO estimate of **visually impaired** people in 2010. n = 39 mill



Mortality from NCDs in 2016



Why Sub Saharan Africa?

Fulfil mandate for diversity in clinical trials

Unmet medical needs particularly for treatment of NCDs

Size and growth of Sub Saharan Africa supports further access and development initiatives



Infectious Disease trials experience paving way for NCD trials

Clinical trials will enable HCP's knowledge and expertise in managing disease conditions


Clinical trials will enable access to innovative molecules

Clinical trials in Africa:

Benefits for patients

- Access to Novartis' broader portfolio of innovative medicines
- Pharma companies are ethical responsible to have products registered in countries where clinical trials have been conducted
- Dissemination of medical knowledge and effective medical practice.
- Unique opportunity for studying NCDs in special populations e.g. HIV co-infections
- Collection of data on race and/or ethnicity that will be important in determining risk-benefit in the local population.
- Identification of population-specific signals that may lead to better patient outcomes.


Current Novartis clinical trial status in SSA



*Key countries

Conclusion

- While the greatest need for new treatment modalities in developing countries continues to be for infectious diseases, **non-communicable diseases are responsible for an increasing proportion of disease burden.**
- Our **portfolio of established medicines** and our **development programmes in tropical diseases** are together ideally positioned to address this **dual challenge.**
- We have additional **opportunities to address unmet needs in low and lower-middle** income countries via investment in the conduct of Novartis clinical trials in select countries within SSA.
- This is core to our mission of *reimagining medicine to improve and extend people's lives.*





20 - 21 July 2021 ● apc2021.pincrowdevents.com ● #APC2021

Thank you!